South Africa has one of the highest UV radiation indices in the world, and a large proportion of the population — particularly those with lighter Fitzpatrick skin types — faces substantial lifetime melanoma risk. But melanoma is a condition where early-stage costs and late-stage costs are wildly different: a Stage I excision costs R20,000–R50,000 and is usually curative; Stage IV melanoma treated with combination immunotherapy costs R800,000–R1.2 million per year and may not be curable. Understanding what your medical aid is required to fund at each stage is essential.
What Is Melanoma?
Melanoma is a malignant tumour arising from melanocytes — the pigment-producing cells of the skin. It is the most dangerous form of skin cancer because of its early propensity to metastasise (spread) via lymphatics and bloodstream to lymph nodes, lungs, liver, brain, and bone.
Melanoma is staged I–IV: - Stage I: Thin, localised tumour; excision with adequate margins is curative in most cases. - Stage II: Thicker or ulcerated tumour, still localised; surgery ± sentinel lymph node biopsy (SLNB). - Stage III: Regional lymph node involvement; surgery + adjuvant systemic therapy. - Stage IV: Distant metastases; systemic treatment required; prognosis historically poor, but dramatically improved since 2011 with immunotherapy and targeted therapy.
Melanoma subtype matters: - BRAF V600E/K mutation (present in ~50% of cutaneous melanomas): Opens access to BRAF/MEK inhibitor combination therapy (dabrafenib + trametinib). - Wild-type (BRAF negative): BRAF inhibitors do not apply; immunotherapy is the primary systemic option. - Acral lentiginous melanoma: More common in patients with darker skin types; arises on palms, soles, and nail beds; different biological profile. - Uveal melanoma (eye): Rare; arises in the choroid of the eye; different treatment pathway.
How Common Is Melanoma in South Africa?
The National Cancer Registry confirms melanoma as one of the more common cancers in white South Africans. South Africa's UV index (8–12+ in summer in most regions) is among the highest globally. Outdoor occupations, sport culture, and historically low sunscreen use create a high cumulative UV exposure.
Melanoma in Black, Coloured, and Indian South Africans is less common but not rare — acral lentiginous melanoma occurs at comparable rates across skin types and is often detected later because of its atypical presentation (under the nail, on the sole of the foot).
Is Melanoma a PMB Condition?
Yes. Melanoma is covered under the Prescribed Minimum Benefits as a Level 1 oncological condition. All registered schemes must fund:
- Diagnosis: Dermatologist assessment, excisional biopsy, histopathology.
- Staging: Sentinel lymph node biopsy (SLNB), CT or PET/CT staging.
- Surgery: Wide local excision (WLE), lymph node dissection where indicated.
- Adjuvant treatment: For Stage III, adjuvant pembrolizumab or nivolumab is now the international standard — but this is exceptional-needs in South Africa (see below).
- Metastatic treatment: Systemic therapy — either targeted (BRAF/MEK inhibitors) or immunotherapy — is the treatment for Stage IV, but again most of this is exceptional-needs.
The critical PMB gap: For early-stage melanoma (Stage I–II), the PMB minimum includes the standard treatment. For Stage III–IV, the PMB minimum standard (surgery, standard chemotherapy with dacarbazine) is woefully inadequate compared to modern treatment, and patients who cannot access targeted therapy or immunotherapy face a significantly worse prognosis. The exceptional-needs process is therefore extremely important for advanced melanoma.
How Does Medical Aid Cover Melanoma?
| Treatment | PMB Status | Notes |
|---|---|---|
| Dermatologist consultation and biopsy | Yes — diagnostic PMB | |
| Wide local excision (surgery) | Yes — PMB | At DSP rates |
| Sentinel lymph node biopsy | Yes — PMB staging | |
| Complete lymph node dissection | Yes — PMB | Where clinically indicated |
| BRAF/MEK testing (molecular) | Varies by scheme | Required to prescribe targeted therapy |
| Adjuvant pembrolizumab (Stage III) | No — exceptional needs | Standard of care internationally; not automatic PMB in SA |
| Dabrafenib + trametinib (BRAF+ Stage III–IV) | No — exceptional needs | Requires BRAF test result |
| Pembrolizumab / nivolumab (Stage IV, BRAF−) | No — exceptional needs | |
| Ipilimumab + nivolumab (metastatic) | No — exceptional needs | High response rate; very high cost |
| Dacarbazine chemotherapy (Stage IV) | Yes — PMB minimum | Largely superseded clinically |
| Brain metastasis: stereotactic radiosurgery | Yes — PMB where indicated |
Day-to-Day Costs: What to Budget For
Stage I–II (early disease): - Dermatologist: R1,000–R2,000 per consultation - Wide local excision: R15,000–R40,000 (procedure + anaesthesia + pathology) - Annual surveillance skin checks: R1,000–R2,000 per visit - SLNB (Stage IB and above): R20,000–R40,000 - Annual cost: R20,000–R80,000
Stage III–IV (advanced disease):
| Scenario | Estimated Annual Cost |
|---|---|
| Stage III, adjuvant pembrolizumab (exceptional needs) | R500,000 – R800,000 |
| Stage IV BRAF+, dabrafenib + trametinib | R400,000 – R700,000 |
| Stage IV, pembrolizumab monotherapy | R450,000 – R750,000 |
| Stage IV, ipilimumab + nivolumab combination | R700,000 – R1,200,000+ |
These costs reflect the medicines alone. Specialist shortfalls, imaging, and hospitalisation are additional.
Gap Cover Relevance
Gap cover is relevant for melanoma: - Dermatologist / plastic surgeon: Wide local excision and reconstruction shortfalls (R10,000–R30,000 per procedure). - Surgical oncologist: Lymph node dissection shortfalls. - Medical oncologist: Infusion fees for immunotherapy and chemotherapy. - Radiologist: PET/CT interpretation. - Neurosurgeon / radiation oncologist: Brain metastasis treatment.
For Stage I–II patients, gap cover comfortably covers expected shortfalls. For Stage IV patients on combination immunotherapy, shortfalls plus medicine costs can far exceed both the gap OPL and the oncology sub-limit within a single year.
Key Questions to Ask Your Scheme
- Is BRAF mutation testing funded? This is essential before prescribing BRAF/MEK inhibitors and should be part of the PMB diagnostic workup.
- What is my oncology sub-limit? For Stage III–IV, this is the most important number.
- Has the scheme funded exceptional-needs applications for pembrolizumab or dabrafenib previously? Track records vary across schemes.
- Is my treating dermatologist / surgical oncologist in the DSP network? Melanoma surgeons are specialists — confirm network status.
- Does the scheme cover surveillance dermoscopy / total body photography for high-risk patients? Preventive monitoring in high-risk families (FAMMM syndrome, multiple atypical nevi) — not automatically covered.
Talk to Eldon
For Stage III–IV melanoma, the oncology sub-limit and exceptional-needs track record of your scheme are decisive. AURA analyses these factors across 112 plans so you can see the real cost difference before choosing.
See which plans pay for melanoma cover →